Eli Lilly on Wednesday said its experimental pill led to more weight loss and better control of blood sugar in patients with ...

Semaglutide is linked to significant weight loss and glucose levels in adults with schizophrenia, overweight/obesity, and ...

In a late-stage trial, an investigational GLP-1 pill from Eli Lilly helped diabetes patients lower their blood sugar and ...

Eli Lilly LLY announced positive top-line data from a late-stage head-to-head study evaluating its once-daily small molecule (non-peptide) oral GLP-1 receptor agonist, orforglipron, compared to Novo ...

PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction ...

Eli Lilly took a major step forward in the GLP-1 arms race with positive data supporting its obesity pill. On Tuesday morning, the pharma giant announced that its oral GLP-1 drug orforglipron ...

i Superiority test was adjusted for multiplicity with all three doses. ii Superiority test was adjusted for multiplicity with the 12 mg and 36 mg doses. For the treatment-regimen estimand, each dose ...

Drugmaker Eli Lilly says its daily oral GLP-1 pill may help people who have obesity and people with Type 2 diabetes lose approximately 23 pounds or more than 10% of their body weight on average, ...

So the, the question we're investigating in this study is whether the use of GLP-1 receptor agonists, which is *** medication for weight loss and diabetes, um, is associated with *** lower risk of ...

Real-world patients prescribed the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy; Novo Nordisk) do lose weight and see an improvement in cardiovascular risk factors, but a new ...

Eli Lilly (NYSE: LLY) saw its shares climb 5% this past week after announcing that its history-making oral obesity candidate, orforglipron aced the Phase III ATTAIN-2 trial (NCT05872620), which ...